Research progress of phosphodiesterase inhibitors in inflammatory bowel disease treatment.
10.3724/zdxbyxb-2021-0170
- Author:
Jianrong SHI
1
;
Wangqian MA
1
;
Huifang TANG
1
Author Information
1. 3. Department of Pharmacology, School of Basic Medical Sciences, Zhejiang University, Hangzhou 310058, China.
- Publication Type:Review
- Keywords:
Cyclic adenosine monophosphate;
Cyclic guanosine monophosphate;
Inflammatory bowel disease;
Phosphodiesterase;
Phosphodiesterase inhibitor;
Review
- MeSH:
Animals;
Colitis;
Inflammatory Bowel Diseases/drug therapy*;
Phosphodiesterase 4 Inhibitors
- From:
Journal of Zhejiang University. Medical sciences
2021;50(5):659-665
- CountryChina
- Language:English
-
Abstract:
Inflammatory bowel disease is a recurrent chronic intestinal inflammatory disease with unknown etiology and no effective treatment. Phosphodiesterase (PDE) regulates a variety of physiological and pathophysiological processes by mediating the hydrolysis of intracellular second messengers cyclic adenosine monophosphate and cyclic guanosine monophosphate. In recent years, a series of researches suggest that PDE inhibitors such as several PDE4 inhibitors, PDE5 inhibitors (sildenafil, tadalafil and vardenafil), PDE3 inhibitors (cilostazol), PDE9 inhibitor (PF-04447943) and PDE3/PDE4 double inhibitor (pumafentrine) have ameliorating effect on experimental colitis in animals. In clinical trials, PDE4 inhibitor apremilast showed more therapeutic advantage than tetomilast. This article reviews the recent research progress of PDE inhibitors in treatment of inflammatory bowel disease.
